COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS

Фармакоэкономика

I. A. Komarov¹  A. Yu. Kulikov¹  R. I. Yagudina¹ 

[1] State Federal-Funded Educational Institution of Higher Vocational Training I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation;

关键词: фармакоэкономический анализ;    хронический миелолейкоз;    терапия первой линии;    ингибиторы тирозинкиназы;    нилотиниб;    тасигна;    иматиниб;    гливек;    анализ «затраты- эффективность»;    анализ «затраты-полезность»;    оценка технологий здравоохранения;   

DOI  :  

来源: DOAJ

【 摘 要 】

Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first-line therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant or acceptable according to used time horizons.

【 授权许可】

Unknown